The Hippo

HOME| ADVERTISING | CONTACT US|

» » »

Blood Thinners Nashua NH

After years of little progress, three new trials suggest that the latest generation of blood thinners may outperform the old standbys warfarin and clopidogrel (Plavix). In one study, dabigatran etexilate (marketed as Pradax in Canada and Pradaxa in Europe; it is not yet approved in the United States) proved to be safe in preventing blood clots when patients were treated for acute coronary syndrome, a cluster of symptoms that might indicate a heart attack.

Steven Lee Schwartz, MD
(603) 577-2039
PO Box 1184
Nashua, NH
Specialties
Cardiology, Internal Medicine
Gender
Male
Education
Medical School: Suny-Hlth Sci Ctr At Brooklyn, Coll Of Med, Brooklyn Ny 11203
Graduation Year: 1984
Hospital
Hospital: Lahey Clinic, Burlington, Ma; Southern New Hampshire Regiona, Nashua, Nh
Group Practice: Lahey Cardiology

Data Provided by:
Steven Paul Beaudette, MD
(603) 883-5673
166 Kinsley St
Nashua, NH
Specialties
Cardiology
Gender
Male
Education
Medical School: Tufts Univ Sch Of Med, Boston Ma 02111
Graduation Year: 1988

Data Provided by:
Yuka Endo, MD
(603) 549-7089
22 Bay Ridge Dr Apt L
Nashua, NH
Specialties
Cardiology
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Paul Francis Boffetti
(603) 577-2780
8 Prospect St
Nashua, NH
Specialty
Cardiology, Internal Medicine

Data Provided by:
Peter Sam Hacker
(603) 883-2226
30 Dearborn St
Nashua, NH
Specialty
General Practice, Cardiology

Data Provided by:
Wendi A Cardeiro, MD, FACC
(603) 577-2039
PO Box 1184
Nashua, NH
Specialties
Cardiology
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Wendi Cardeiro
(603) 577-2039
8 Prospect St
Nashua, NH
Specialty
Cardiology, Cardiovascular Disease

Data Provided by:
Peter Tabor Klementowicz, MD
(603) 883-5673
166 Kinsley St Ste 301
Nashua, NH
Specialties
Cardiology
Gender
Male
Education
Medical School: Tufts Univ Sch Of Med, Boston Ma 02111
Graduation Year: 1978

Data Provided by:
William Timothy Larney, MD
(603) 579-9631
280 Main St
Nashua, NH
Specialties
Cardiology
Gender
Male
Education
Medical School: New York Med Coll, Valhalla Ny 10595
Graduation Year: 1974

Data Provided by:
Mark Joel Liebling, MD
(603) 883-5673
166 Kinsley St Ste 301
Nashua, NH
Specialties
Cardiology
Gender
Male
Education
Medical School: A Einstein Coll Of Med Of Yeshiva Univ, Bronx Ny 10461
Graduation Year: 1975

Data Provided by:
Data Provided by:

Blood Thinners

Provided By:

WEDNESDAY, Nov. 18 (HealthDay News) -- After years of little progress, three trials suggest that the latest generation of blood thinners may outperform the old standbys warfarin and clopidogrel (Plavix).

In one study, dabigatran etexilate (marketed as Pradax in Canada and Pradaxa in Europe; it is not yet approved in the United States) proved to be safe in preventing blood clots when patients were treated for acute coronary syndrome, a cluster of symptoms that might indicate a heart attack.

"Dabigatran seems to be safe on top of dual antiplatelet therapy [meaning aspirin and Plavix]," said study author Dr. Jonas Oldgren, chief physician in the department of cardiology at Uppsala University Hospital in Uppsala, Sweden. "It has already been shown to have superior efficacy compared with warfarin."

A previous trial had demonstrated that dabigatran outperformed warfarin in preventing strokes in patients with atrial fibrillation.

The current trial, to be presented Wednesday at the American Heart Association's annual meeting in Orlando, Fla., also saw a reduction in mortality, nonfatal heart attack and stroke, although it was not specifically designed to look at efficacy.

"Dabigatran appears to be superior to warfarin in terms of safety and more effective as well. This is the first alternative to warfarin that could signal a changing of the guard," said Dr. Bernard Gersh, a professor of medicine at the Mayo Clinic College of Medicine in Rochester, Minn. "I think there are still questions that need to be answered but it's fair to say that warfarin has been around for many, many years and everybody hates warfarin. Patients hate warfarin. Doctors hate warfarin. It's not the most convenient drug, but it's effective and it is cheap."

The trial involved more than 1,800 patients in 24 countries with acute coronary syndrome who were randomized to receive one of four doses of dabigatran, made by Boehringer Ingelheim, or a placebo. All participants were also taking aspirin and Plavix.

"It's premature to say that a drug like dabigatran will take the place of warfarin," Gersh said. "There will be a lot of discussion about cost and convenience. It's a twice-daily dose and there are some questions about a possible higher rate of heart attack. I don't think this is truly resolved yet, but I think we can say that for the first time we have seen a drug that certainly has the potential to be an alternative to warfarin, and maybe even superior."

Two other trials, both presented at the heart association meeting and published in the Nov. 18 issue of Circulation, looked at an anti-clotting pill called ticagrelor (Brilinta), comparing its performance with clopidogrel (Plavix). Brilinta, made by AstraZeneca, is also awaiting approval from the U.S. Food and Drug Administration.

Prior Brilinta studies found that it was better than Plavix in preventing new heart attacks and preventing deaths among patients who had already had a heart attack.

In the first of the two latest trials, both conducted by researchers at Sinai Hospital in Baltimore, 123 patients with stable coronary artery disease who were also taking aspirin were randomized to Brilinta, Plavix or a placebo for six weeks.

Brilinta evoked a response in patients who did not respond to Plavix. It also could be turned off faster, meaning patients could go into surgery right away if needed, and lasted longer.

The second Brilinta study showed that 98 patients who didn't respond to Plavix did respond to Brilinta.

All of this just signals the beginning of a new round of anti-clotting medications, experts said.

"There are several trials ongoing of other alternatives to warfarin. We will probably see results in the next two years," Gersh said.

More information

Visit the American Heart Association for more on blood thinners.

Author: By Amanda Gardner
HealthDay Reporter

SOURCES: Bernard Gersh, M.D., professor, medicine, Mayo Clinic College of Medicine, Rochester, Minn.; Nov. 18, 2009, news conference with: Jonas Oldgren, M.D., chief physician, cardiology, Uppsala University Hospital, Uppsala, Sweden; Nov. 18, 2009, presentations, American Heart Association annual meeting, Orlando, Fla.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu